Lamotrigine and Psoriasis - a phase IV clinical study of FDA data

Summary:

Psoriasis is reported as a side effect among people who take Lamotrigine (lamotrigine), especially for people who are female, 40-49 old, have been taking the drug for 1 - 6 months also take Otezla, and have Psoriatic arthropathy.

The phase IV clinical study analyzes which people have Psoriasis when taking Lamotrigine. It is created by eHealthMe based on reports of 72,834 people who have side effects when taking Lamotrigine from the FDA, and is updated regularly.

What is Lamotrigine?

Lamotrigine has active ingredients of lamotrigine. It is often used in bipolar disorder. eHealthMe is studying from 76,638 Lamotrigine users. Check the latest studies of Lamotrigine.

What is Psoriasis?

Psoriasis (immune-mediated disease that affects the skin) is found to be associated with 1,481 drugs and 1,695 conditions by eHealthMe. Check the latest studies of Psoriasis.

On Apr, 15, 2026

72,834 people reported to have side effects when taking Lamotrigine.
Among them, 263 people (0.36%) have Psoriasis.

Among these 263 people:

* Approximation only. Some reports may have incomplete information.

Do you take Lamotrigine and have Psoriasis?

- Check whether Psoriasis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lamotrigine:

Lamotrigine (76,638 reports)

Psoriasis treatments and more:

Psoriasis (508,163 reports)

How severe was Psoriasis and when was it recovered:

Psoriasis in Lamotrigine

Expand to all the drugs that have ingredients of lamotrigine:

Psoriasis and drugs with ingredients of lamotrigine (457 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Lamotrigine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Psoriasis:

Psoriasis (1,481 drugs)

Browse all the conditions that are associated with Psoriasis:

Psoriasis (1,695 conditions)

Related publications that referenced our studies

Mohagheghi MA, Omranipur R, Ensani F, Ghannadan A, Shahriaran S, Samiee F, Sedighi Z, "A Case of Advanced Unicentric Retroperitoneal Castleman's Disease, Associated With Psoriasis", Acta Medica Iranica, 2017 May .
Alonso-Navarro H, Montes JM, Plaza-Nieto JF, Jiménez-Jiménez FJ, "Cataplexy Possibly Associated With Lamotrigine", Journal of clinical psychopharmacology, 2016 Aug .
Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
Gupta MC, Khanna J, Mathur R, Mittal N, "Lamotrigine-induced fulminant hepatic failure: an unusual presentation", IMSEAR, 2015 Jan .
Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .
Mohagheghi MA, Omranipur R, Ensani F, Ghannadan A, Shahriaran S, Samiee F, Sedighi Z, "A Case of Advanced Unicentric Retroperitoneal Castleman's Disease, Associated With Psoriasis", Acta Medica Iranica, 2017 May .
Alonso-Navarro H, Montes JM, Plaza-Nieto JF, Jiménez-Jiménez FJ, "Cataplexy Possibly Associated With Lamotrigine", Journal of clinical psychopharmacology, 2016 Aug .
Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
Gupta MC, Khanna J, Mathur R, Mittal N, "Lamotrigine-induced fulminant hepatic failure: an unusual presentation", IMSEAR, 2015 Jan .
Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on lamotrigine (the active ingredients of Lamotrigine) and Lamotrigine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.